Results of bevacizumab as the primary treatment for retinal vein occlusions.
about
Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusionEfficacy of combined intravitreal bevacizumab and triamcinolone for branch retinal vein occlusion.Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results.Intravitreal injection of bevacizumab combined with macular grid laser photocoagulation for macular edema in branch retinal vein occlusion.The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.Intravitreal bevacizumab treatment for macular edema due to branch retinal vein occlusion in a clinical setting.Indications for intravitreal bevacizumab in ibadan, sub-saharan Africa.Branch retinal vein occlusion: treatment modalities: an update of the literature.Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion.Retinal vein occlusion and macular edema - critical evaluation of the clinical value of ranibizumab.Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion.Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panelPractical management of retinal vein occlusions.Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions.Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion.5-Fluorouracil vs avastin as adjunct to conjunctival autograft in the surgical treatment of pterygium.Management of retinal vein occlusion--consensus document.Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment.Bevacizumab treatment for acute branch retinal vein occlusion accompanied by subretinal hemorrhage.Hemiretinal vein occlusion with macular hemorrhage and edema treated with intravitreal bevacizumab.Subconjunctival bevacizumab for primary pterygium excision; a randomized clinical trial.Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results.Initial dose of three monthly intravitreal injections versus PRN intravitreal injections of bevacizumab for macular edema secondary to branch retinal vein occlusion.Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion.SCORE2 Report 2: Study Design and Baseline Characteristics.Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion-related macular oedema: a prospective randomized comparison.Predicting the visual acuity for retinal vein occlusion after ranibizumab therapy with an original ranking for macular microstructure.Bevacizumab versus Dexamethasone Implant Followed by Bevacizumab for the Treatment of Macula Edema Associated with Branch Retinal Vein Occlusion.Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity.Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naïve patients with retinal vein occlusion and macular edema: a 12-month follow-up study.Potential anti-vascular endothelial growth factor therapies for central retinal vein occlusion.
P2860
Q24201821-EDAE5E71-68C1-4EBB-80D3-FD5E87F8BFDDQ33780636-AD507DE1-CAEA-49DE-9CEA-8D5EAB40944EQ33959122-5512CE26-88F2-415A-B379-A3631ECF4C88Q34016748-13AD3BAB-AC4E-4167-A4F6-4DEB7CB1C46EQ34115840-A2095832-2F9C-44BD-9039-A298DACAA958Q34293412-D0AAAD2B-E53C-46B5-836D-19E9444F32A1Q34648669-E1A81F66-06DC-4E54-A894-DAADE71B60B5Q35028773-881D17F9-643D-4745-891E-268ED69D72DEQ35038286-34DDB28B-AB6B-4D16-B56B-705CA3484A2FQ35089799-1259FD24-397B-424F-8209-813F78ED997CQ35122731-FB375438-8FDA-4198-A772-41B54D72EDECQ35135745-31FB96EB-5C3D-4C84-891F-D16C99987FC8Q35227614-90E35468-B758-4BC9-89DB-6CCF63C8938AQ35635355-0518AB02-C47F-41DB-97B0-8BFA53D97BBFQ36951463-0CDE7B39-DD68-4C70-BC5C-391970A44FC1Q37413033-05EBFDFB-0A28-4413-A194-51937843CDC7Q37876127-DF6A7D91-1822-484D-97CC-A6962EBD6DF2Q37943001-30AA30E2-6D7A-4F16-B751-18ADA6E68B18Q38261432-178A0C87-59F7-460F-9060-876BF78C0EF7Q38905297-C5636B58-239D-4A92-BCDE-5448FE972971Q41441751-C8F6EB25-29FE-435F-978E-AE6D4177CCF3Q41774096-C1D0CD44-5085-4548-9EAF-FDB9280E84F9Q42181848-5178A5A2-1EFB-4F73-813F-E131808593A5Q42414491-7707357B-5AC2-4B6F-AE38-AD97F76039E8Q46169738-CC0B7491-D3DD-4F56-9FDD-2B340F5DD20DQ46970491-A2FF18E1-0C9D-40DA-AB0B-F3481C891828Q49232014-72059FFC-3A05-4092-ABC0-D88C25A85B09Q49619345-7D7CA47D-5019-4A4B-B14E-7E2251839B4DQ51354430-D6A0CEDC-3646-4FE4-9D5B-96736FC8F8B2Q53619775-89739FE9-190F-485D-9CAC-064598DBDA15Q54477941-E8AE69AB-52C3-409A-941E-BB964655A7DA
P2860
Results of bevacizumab as the primary treatment for retinal vein occlusions.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Results of bevacizumab as the primary treatment for retinal vein occlusions.
@en
Results of bevacizumab as the primary treatment for retinal vein occlusions.
@nl
type
label
Results of bevacizumab as the primary treatment for retinal vein occlusions.
@en
Results of bevacizumab as the primary treatment for retinal vein occlusions.
@nl
prefLabel
Results of bevacizumab as the primary treatment for retinal vein occlusions.
@en
Results of bevacizumab as the primary treatment for retinal vein occlusions.
@nl
P2093
P356
P1476
Results of bevacizumab as the primary treatment for retinal vein occlusions.
@en
P2093
C Arruabarrena
I Contreras
M S Figueroa
P304
P356
10.1136/BJO.2009.173732
P407
P577
2010-08-01T00:00:00Z